In a move that marks a significant escalation in the long-standing war over the federal 340B drug discount program, pharmaceutical giant Eli Lilly has begun cutting off 340B pricing for hospitals that refuse to submit granular claims data. This enforcement action, which follows an ultimatum issued earlier this year, highlights the deepening rift between drug manufacturers, who claim the program is rife with abuse, and hospital systems, who argue that such mandates are both illegal and a threat to patient care.
The conflict centers on a core requirement: Lilly is now demanding that providers submit specific claims data for all of its drugs dispensed through the 340B program. While the policy was announced in January, the company only began enforcing the mandate this month, triggering an immediate backlash from the American Hospital Association (AHA) and 340B Health. As of this week, hospitals that have failed to comply with the data-sharing requirement have been stripped of the ability to purchase Lilly medications at the 340B-mandated discount, which typically ranges from 20% to 50% below wholesale prices.
A Chronology of Escalation
The current impasse is the latest chapter in a multi-year struggle to define the operational boundaries of the 340B program. Created in 1992, the program was designed to allow "covered entities"—primarily safety-net hospitals and clinics—to purchase outpatient drugs at a discount, theoretically allowing them to stretch scarce federal resources to provide more comprehensive services to uninsured and low-income populations.
- Early 2024: Eli Lilly announced a firm policy requiring participating hospitals to submit detailed claims data for all Lilly products dispensed under 340B. The company justified this as a "crucial step" to prevent drug diversion and the systemic issue of "duplicate discounts."
- Spring/Summer 2024: Negotiations between pharmaceutical manufacturers and hospital groups stalled. Despite pushback, Lilly maintained that the data requirement was necessary for program integrity.
- January 2025: Lilly formally announced that it would begin enforcing the data-sharing mandate.
- February 2025: Following a period of non-compliance by several "well-resourced" hospitals, Lilly initiated the termination of 340B pricing for those facilities.
- Present Day: The industry awaits further intervention from the Health Resources and Services Administration (HRSA), as hospital advocates call for federal action to prevent a total erosion of the 340B framework.
The Financial Impact: Why Data Sharing Matters
For the affected hospitals, the loss of 340B pricing is a financial blow of significant proportions. The program has grown at an extraordinary rate; in 2023, 340B purchases hit a record $66.3 billion, a staggering increase from the $43.9 billion recorded just two years prior.
This growth has not gone unnoticed by policymakers or the pharmaceutical industry. Critics, including the Congressional Budget Office (CBO), have pointed to the expansion of hospital-owned clinics and complex pharmacy contract networks as drivers of this "snowballing" spending. Manufacturers argue that without transparency—provided through the claims data Lilly is requesting—there is no way to audit whether a drug is being dispensed to an eligible patient or if a hospital is improperly receiving both a 340B discount and a Medicaid rebate for the same medication.
For the hospitals, however, the financial loss is compounded by the lack of statutory authority for such demands. Hospital lobbies argue that the 340B statute does not grant drugmakers the right to make discounts conditional on data submission. When a hospital is forced to pay wholesale prices, the surplus revenue that was previously used to subsidize community health initiatives, charity care, and specialized programs effectively evaporates.
Official Responses: A Clash of Legal Interpretations
The disagreement has devolved into a battle over statutory interpretation. Eli Lilly maintains that its actions are consistent with decades of regulatory guidance that encourages manufacturers to take steps to prevent drug diversion. In a letter to HRSA, the agency tasked with overseeing the program, Lilly representatives expressed that the move was taken "reluctantly" after voluntary compliance efforts failed to gain traction among major hospital systems.
On the other side, the rhetoric is increasingly combative. Maureen Testoni, president and CEO of 340B Health, which represents over 1,600 hospitals, did not mince words regarding the legality of the move. "We believe Lilly’s actions violate the law and are an unprecedented attempt to rewrite the 340B rules without congressional approval," Testoni stated.
Rick Pollack, president and CEO of the AHA, echoed this sentiment, calling for immediate federal intervention. "HRSA and HHS cannot continue to stand by while Eli Lilly and others rewrite the rules for their own benefit and skirt their obligations," Pollack said. Despite these pleas, HRSA has declined to comment on the record regarding whether it intends to take enforcement action against Lilly.
Implications for the Healthcare Landscape
The fallout from this standoff extends well beyond the balance sheets of the affected hospitals. There is a pervasive fear among health policy experts that if Lilly’s policy is allowed to stand, it will set a dangerous precedent.
The Domino Effect
Other pharmaceutical companies are already watching the situation closely. Novo Nordisk has already begun implementing its own data-sharing requirements, signaling that the industry is moving toward a coordinated push for greater control over 340B transparency. If regulators fail to push back, industry observers expect a "race to the bottom" where every manufacturer imposes unique, burdensome data requirements on hospitals, effectively turning the 340B program into an administrative nightmare.
The Rebate Debate Revisited
This is not the first time drugmakers have attempted to unilaterally change the program’s mechanics. In 2024, a cadre of manufacturers, including Lilly, attempted to transition from upfront discounts to a rebate-based system, where hospitals would pay full price and receive a refund only after proving the eligibility of the claim. That effort was largely halted by federal courts, which agreed that manufacturers lacked the legal standing to alter the payment structure of a congressionally mandated program.
The current data-sharing ultimatum is viewed by many as "Plan B"—a way for manufacturers to exert control over the program’s flow without necessarily changing the payment method itself.
The Future of 340B Oversight
The political climate surrounding the program is also shifting. While the Trump administration previously expressed interest in exploring rebate pilots, the current oversight environment remains fragmented. The lack of clear parameters on how hospitals must use 340B savings has led to increasing scrutiny from Congress. Lawmakers are divided: some view the program as a vital lifeline for safety-net providers, while others view it as an opaque, bloated system that has strayed far from its original mission of helping the underserved.
Conclusion: A System at a Crossroads
The standoff between Eli Lilly and the nation’s hospitals is a microcosm of a broader, systemic struggle within the American healthcare sector. As 340B continues to represent a larger share of drug spending, the friction between the desire for transparency and the need for hospital financial stability will only intensify.
If HRSA remains on the sidelines, the current situation may serve as the catalyst for a fundamental legislative overhaul. Without a clear signal from regulators or a compromise from industry stakeholders, the 340B program risks becoming a battleground of litigation and non-compliance, ultimately harming the patients who rely on the safety-net services it was designed to support. For now, the hospitals caught in Lilly’s crosshairs face an uncertain future, forced to weigh the cost of compliance against the potential loss of a program that has been essential to their operations for over thirty years.
About the Author
